Nektar Therapeutics (NKTR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $35.78, -5.14% vs the prior close of $37.72.
- Volume 784.23K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NKTR slides 5.1% to $35.78, a 6-month low. Closed at $35.78, -5.14% vs the prior close of $37.72. Day range $35.62–$38.05, opened at $38.05.
NKTR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NKTR slides 5.1% to $35.78, a 6-month low
- Closed at $35.78, -5.14% vs the prior close of $37.72. Day range $35.62–$38.05, opened at $38.05.
- Volume was 784.23K shares, 0.6x its 50-day average of 1.22M.
- Price is -43.2% vs its 50-day average ($63.02) and -45.1% vs its 200-day average ($65.14).
- 52-week range $33.40–$109.00; today's close sits at 3% of that range, 67.2% below the 52-week high.
Oct 15, 2026 — NKTR rises 2.2% to $37.72
- Closed at $37.72, +2.25% vs the prior close of $36.89. Day range $36.94–$38.74, opened at $37.15.
- Volume was 684.20K shares, 0.6x its 50-day average of 1.22M — lighter than usual.
- Price is -40.9% vs its 50-day average ($63.77) and -42.1% vs its 200-day average ($65.17).
- 52-week range $33.40–$109.00; today's close sits at 6% of that range, 65.4% below the 52-week high.
Oct 14, 2026 — NKTR dips 2.7% to $36.89, a 6-month low, 3 down days in a row
- Closed at $36.89, -2.72% vs the prior close of $37.92. Day range $36.56–$37.75, opened at $37.50.
- Volume was 999.70K shares, 0.8x its 50-day average of 1.21M.
- Price is -42.8% vs its 50-day average ($64.48) and -43.4% vs its 200-day average ($65.20).
- 52-week range $33.40–$109.00; today's close sits at 5% of that range, 66.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — NKTR slides 4.8% to $37.92, a 6-month low
- Closed at $37.92, -4.82% vs the prior close of $39.84. Day range $37.75–$39.83, opened at $39.79.
- Volume was 2.04M shares, 1.7x its 50-day average of 1.18M.
- Price is -41.8% vs its 50-day average ($65.20) and -41.9% vs its 200-day average ($65.24).
- 52-week range $33.40–$109.00; today's close sits at 6% of that range, 65.2% below the 52-week high.
Oct 12, 2026 — NKTR slides 3.2% to $39.84, a 6-month low
- Closed at $39.84, -3.23% vs the prior close of $41.17. Day range $39.26–$40.98, opened at $40.93.
- Volume was 1.05M shares, 0.9x its 50-day average of 1.17M.
- Price is -39.5% vs its 50-day average ($65.85) and -39.0% vs its 200-day average ($65.27).
- 52-week range $33.40–$109.00; today's close sits at 9% of that range, 63.4% below the 52-week high.
Oct 9, 2026 — NKTR rises 0.9% to $41.17, 3 up days in a row
- Closed at $41.17, +0.91% vs the prior close of $40.80. Day range $40.33–$42.38, opened at $40.38.
- Volume was 1.17M shares, 1.0x its 50-day average of 1.16M.
- Price is -38.1% vs its 50-day average ($66.47) and -36.9% vs its 200-day average ($65.29).
- 52-week range $33.40–$109.00; today's close sits at 10% of that range, 62.2% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — NKTR rises 1.3% to $40.80
- Closed at $40.80, +1.34% vs the prior close of $40.26. Day range $39.01–$41.14, opened at $39.89.
- Volume was 1.75M shares, 1.5x its 50-day average of 1.15M.
- Price is -39.2% vs its 50-day average ($67.07) and -37.5% vs its 200-day average ($65.30).
- 52-week range $33.40–$109.00; today's close sits at 10% of that range, 62.6% below the 52-week high.
Oct 7, 2026 — NKTR rises 0.9% to $40.26
- Closed at $40.26, +0.88% vs the prior close of $39.91. Day range $38.45–$40.35, opened at $39.22.
- Volume was 1.51M shares, 1.3x its 50-day average of 1.13M.
- Price is -40.5% vs its 50-day average ($67.67) and -38.4% vs its 200-day average ($65.33).
- 52-week range $33.40–$109.00; today's close sits at 9% of that range, 63.1% below the 52-week high.
Oct 6, 2026 — NKTR slides 5.5% to $39.91, a 6-month low, 4 down days in a row
- Closed at $39.91, -5.47% vs the prior close of $42.22. Day range $39.34–$42.44, opened at $42.44.
- Volume was 1.96M shares, 1.8x its 50-day average of 1.11M.
- Price is -41.6% vs its 50-day average ($68.28) and -38.9% vs its 200-day average ($65.35).
- 52-week range $33.40–$109.00; today's close sits at 9% of that range, 63.4% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — NKTR slides 3.1% to $42.22, a 6-month low on 1.9x normal volume
- Closed at $42.22, -3.12% vs the prior close of $43.58. Day range $41.35–$43.50, opened at $43.50.
- Volume was 2.03M shares, 1.9x its 50-day average of 1.08M — unusually heavy trading.
- Price is -38.7% vs its 50-day average ($68.91) and -35.4% vs its 200-day average ($65.38).
- 52-week range $33.40–$109.00; today's close sits at 12% of that range, 61.3% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — NKTR slides 7.3% to $43.58, a 6-month low on 2.8x normal volume
- Closed at $43.58, -7.26% vs the prior close of $46.99. Day range $43.51–$47.13, opened at $47.09.
- Volume was 2.92M shares, 2.8x its 50-day average of 1.04M — unusually heavy trading.
- Price is -37.3% vs its 50-day average ($69.48) and -33.4% vs its 200-day average ($65.41).
- 52-week range $33.40–$109.00; today's close sits at 13% of that range, 60.0% below the 52-week high.
NKTR latest news & SEC filings
Every SEC filing by or about NKTR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 28, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Whitfield Roy A received an award of 2,000 shares on Sep 23, 2026; now holds 16,417
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Greer R Scott received an award of 2,000 shares on Sep 23, 2026; now holds 22,239
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Chess Robert received an award of 2,000 shares on Sep 23, 2026; now holds 19,019
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Brainard Diana received an award of 2,000 shares on Sep 23, 2026; now holds 3,904
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ajer Jeffrey Robert received an award of 2,000 shares on Sep 23, 2026; now holds 4,277
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Zalevsky Jonathan sold 186 shares at $71.98 (≈$13.39K) on Aug 18, 2026
- Zalevsky Jonathan sold 186 shares at $71.98 (≈$13.39K) on Aug 18, 2026
- Zalevsky Jonathan sold 186 shares at $71.98 (≈$13.39K) on Aug 18, 2026
- Zalevsky Jonathan sold 186 shares at $71.98 (≈$13.39K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $10.13M (prior year $11.18M) (-9.3% vs Jun 30, 2025)
- Net income: -$40.62M (prior year -$41.59M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.23 (prior year -$2.95) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade NKTR
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 12, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.55% (largest 22.4%). That is a volatile stock.
- Liquidity: about 1.95M shares (≈$69.66M) trade per day on average.
- 52-week position: $35.78 vs a range of $33.40–$109.00 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:15 on Jun 9, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Howard W Robin sold 418 shares on Aug 18, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 25, 2026; 8-K Sep 8, 2026.
- Share count: 34.14M shares outstanding (Aug 7, 2026), +79.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NKTR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 38.05 | 38.05 | 35.62 | 35.78 | 784.23K |
| Oct 15, 2026 | 37.15 | 38.74 | 36.94 | 37.72 | 684.20K |
| Oct 14, 2026 | 37.50 | 37.75 | 36.56 | 36.89 | 999.70K |
| Oct 13, 2026 | 39.79 | 39.83 | 37.75 | 37.92 | 2.04M |
| Oct 12, 2026 | 40.93 | 40.98 | 39.26 | 39.84 | 1.05M |
| Oct 9, 2026 | 40.38 | 42.38 | 40.33 | 41.17 | 1.17M |
| Oct 8, 2026 | 39.89 | 41.14 | 39.01 | 40.80 | 1.75M |
| Oct 7, 2026 | 39.22 | 40.35 | 38.45 | 40.26 | 1.51M |
| Oct 6, 2026 | 42.44 | 42.44 | 39.34 | 39.91 | 1.96M |
| Oct 5, 2026 | 43.50 | 43.50 | 41.35 | 42.22 | 2.03M |
| Oct 2, 2026 | 47.09 | 47.13 | 43.51 | 43.58 | 2.92M |
| Oct 1, 2026 | 55.41 | 56.69 | 46.29 | 46.99 | 6.27M |
| Sep 30, 2026 | 59.96 | 62.40 | 58.91 | 60.55 | 1.21M |
| Sep 29, 2026 | 60.14 | 60.75 | 57.69 | 59.24 | 1.82M |
| Sep 28, 2026 | 57.00 | 61.40 | 56.40 | 60.40 | 1.38M |
| Sep 25, 2026 | 59.77 | 60.98 | 57.04 | 57.06 | 2.64M |
| Sep 24, 2026 | 58.03 | 61.79 | 56.21 | 59.38 | 2.80M |
| Sep 23, 2026 | 60.40 | 61.00 | 56.92 | 57.66 | 1.84M |
| Sep 22, 2026 | 67.08 | 68.33 | 59.44 | 60.97 | 3.32M |
| Sep 21, 2026 | 68.53 | 69.84 | 66.71 | 66.84 | 765.90K |
About Nektar Therapeutics
Nektar Therapeutics (NKTR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 906709.
NKTR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeffrey Robert Ajer | Director | Sep 25, 2026 |
| Diana Brainard | Director | Sep 25, 2026 |
| Robert Chess | Director | Sep 25, 2026 |
| R Scott Greer | Director | Sep 25, 2026 |
| Howard W Robin | President & CEO | Aug 20, 2026 |
| Roy A Whitfield | Director | Sep 25, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Howard W Robin | President & CEO | Aug 20, 2026 |
| Linda M Rubinstein | Interim CFO | May 26, 2026 |
| Mark Andrew Wilson | Chief Legal Officer | Nov 25, 2025 |
| Jonathan Zalevsky | Chief R&D Officer | Aug 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Howard W Robin | Sale | 418 | $71.98 |
| Aug 18, 2026 | Howard W Robin | Sale | 418 | $71.98 |
| Aug 18, 2026 | Howard W Robin | Sale | 418 | $71.98 |
| Aug 18, 2026 | Howard W Robin | Sale | 418 | $71.98 |
| Aug 18, 2026 | Jonathan Zalevsky | Sale | 186 | $71.98 |
| Aug 18, 2026 | Jonathan Zalevsky | Sale | 186 | $71.98 |
| Aug 18, 2026 | Jonathan Zalevsky | Sale | 186 | $71.98 |
| Aug 18, 2026 | Jonathan Zalevsky | Sale | 186 | $71.98 |
| Jun 30, 2026 | Jonathan Zalevsky | Sale | 5,681 | $70.00 |
| Jun 30, 2026 | Jonathan Zalevsky | Sale | 5,681 | $70.00 |
| Jun 30, 2026 | Jonathan Zalevsky | Sale | 5,681 | $70.00 |
| Jun 30, 2026 | Jonathan Zalevsky | Sale | 5,681 | $70.00 |
| Jun 17, 2026 | Howard W Robin | Sale | 5,500 | $60.81 |
| Jun 17, 2026 | Howard W Robin | Sale | 4,500 | $61.65 |
| Jun 17, 2026 | Howard W Robin | Sale | 5,500 | $60.81 |
NKTR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $55.23M | $-164.08M | -9.73 | $-208.51M |
| Dec 31, 2024 | $98.43M | $-118.96M | -8.68 | $-175.71M |
| Dec 31, 2023 | $90.12M | $-276.06M | -1.45 | $-192.61M |
| Dec 31, 2022 | $92.06M | $-368.20M | -1.97 | $-304.01M |
| Dec 31, 2021 | $101.91M | $-523.84M | -2.86 | $-412.66M |
Latest balance sheet: total assets $1.10B, total liabilities $192.01M, cash $39.27M (as of Jun 30, 2026).
NKTR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $75.92 |
| May 7, 2026 | 8-K Item 2.02 (results) | $83.37 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $70.36 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $55.12 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $21.75 |
| May 8, 2025 | 8-K Item 2.02 (results) | $9.30 |
| Mar 12, 2025 | 8-K Item 2.02 (results) | $12.30 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $20.55 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 4, 2024 | 8-K Item 2.02 (results) | — |
| Jan 10, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NKTR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.